1. Home
  2. ACET vs FBIO Comparison

ACET vs FBIO Comparison

Compare ACET & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.73

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Logo Fortress Biotech Inc.

FBIO

Fortress Biotech Inc.

HOLD

Current Price

$2.23

Market Cap

78.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACET
FBIO
Founded
1947
2006
Country
United States
United States
Employees
N/A
78
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.3M
78.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ACET
FBIO
Price
$7.73
$2.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$48.33
$17.00
AVG Volume (30 Days)
136.8K
448.7K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$55.22
Revenue Next Year
N/A
$40.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$1.62
52 Week High
$9.05
$4.53

Technical Indicators

Market Signals
Indicator
ACET
FBIO
Relative Strength Index (RSI) 52.19 32.80
Support Level $6.28 $2.20
Resistance Level $8.46 $2.71
Average True Range (ATR) 0.47 0.11
MACD 0.03 0.02
Stochastic Oscillator 57.30 1.79

Price Performance

Historical Comparison
ACET
FBIO

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

Share on Social Networks: